权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Repurposing Bazedoxifene for chemoprevention in pre-invasive pancreatic cancer IPMN

重新利用巴多昔芬对浸润前胰腺癌进行化学预防 IPMN

基本信息

批准号：
10540747
负责人：
Iok In Christine Chio
金额：
$ 18.35万
依托单位：
COLUMBIA UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-12-14 至 2023-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10540747
关键词：
3-Dimensional Address Affect Age Aging Binding Cancer Etiology Caring Cell secretion Cells Cessation of life Chemicals Chemoprevention Chemopreventive Agent Chronic Clinical Clinical Trials Complement Complex Data Development Diabetes Mellitus Duct (organ) structure Effectiveness Elderly Epithelial Cells Epithelium Estrogen Receptors Estrogens Excision FDA approved Fibroblasts Genetically Engineered Mouse Growth Guidelines Health Benefit Heterogeneity Histologic Homeostasis Human IL-6 inhibitor IL6 Signaling Pathway IL6ST gene Implant In Vitro Induction of Apoptosis Inflammation Inflammatory Interleukin 6 Receptor Interleukin-1 Interleukin-6 Knowledge Lesion Malignant Neoplasms Malignant neoplasm of pancreas Measures Metabolic Metastatic Neoplasm to the Liver Modeling Molecular Molecular Analysis Molecular Profiling Monitor Morbidity - disease rate Mucinous Neoplasm Mus Mutation NF-kappa B Neoplasm Metastasis Oncogenic Operative Surgical Procedures Oral Organoids Osteoporosis prevention Oxidation-Reduction Pancreas Pancreatic Ductal Adenocarcinoma Pancreatic Intraepithelial Neoplasia Papillary Pathway interactions Patient Care Patients Pharmaceutical Preparations Phenotype Phosphorylation Play Postmenopause Pre-Clinical Model Preventive Preventive measure Preventive therapy Preventive treatment Prognosis Property Proteomics Publishing Research Subjects Resectable Resected Risk Factors Role STAT3 gene Safety Serum Signal Pathway Signal Transduction Survival Rate Testing Translating Tumor Promotion Woman antagonist attenuation cancer invasiveness chronic pancreatitis clinical care clinical practice cytokine receptor gp130 efficacy evaluation high risk high risk population implantation improved in vivo insight mouse model neoplastic cell novel pancreatic cancer cells pancreatic cancer patients pancreatic ductal adenocarcinoma cell pancreatic neoplasm pancreatic stellate cell pancreatic tumorigenesis pre-clinical premalignant prevent promoter protein protein interaction radiological imaging response senescence success tumor tumor growth tumor progression tumorigenic

项目摘要

PROJECT SUMMARY/ABSTRACT Precancerous lesions of pancreatic ductal adenocarcinoma (PDAC) called pancreatic intraductal papillary mucinous neoplasms (IPMN) can be detected radiographically, but monitoring and identifying patients who can benefit from surgical intervention before the development of malignant tumor has been an immense challenge in the management of patients with IPMN. Here we propose to investigate the feasibility of repurposing FDA- approved Bazedoxifene as a chemopreventive therapy for patients with IPMN in preclinical models, which may complement and improve the current care for these patients who are at high-risk for developing PDAC. Using unbiased computational and chemical screens, we have previously identified Bazedoxifene as a novel IL-6 signaling antagonist that can directly bind to GP130, a common component of IL-6 receptor complex. IL- 6/STAT3 is a vital oncogenic signaling axis that promotes pancreatic tumorigenesis. Elevated IL-6 level is associated with inflammation, aging, and poor prognosis and metastasis in pancreatic cancer patients. More recently, IL-6 secretion stimulated by IL-1-NFkB-JAK/STAT signaling is implicated in activating tumor- promoting inflammatory cancer associated fibroblast cells (iCAF). While inhibition of IL-6 and STAT3 to suppress PDAC has been pursued previously, here we propose to explore the uncharted efficacy of Bazedoxifene (a well-tolerated FDA-approved medication that is prescribed for osteoporosis prevention and can be taken orally) as a chemopreventive measure for patients who are identified as high-risk for developing PDAC, specifically those with detectable premalignant IPMN. To test our novel hypothesis that repurposing Bazedoxifene for chemoprevention would block IPMN progression to PDAC via inhibition of IL-6 signaling, we will 1) use 3D organoids derived from our unique mouse model for IPMN and from surgically resected IPMNs from patients to evaluate the functional and molecular impacts of Bazedoxifene as a chemopreventive agent on epithelial cells (Aim 1); 2) use our IPMN mouse model and orthotopically implanted murine and human IPMN 3D organoids to investigate the efficacy of Bazedoxifene as a chemopreventive therapy in vivo (Aims 1 & 2); 3) to investigate if Bazedoxifene also affects the stromal components, specifically the activation of quiescent fibroblast cells and the interconvertibility between CAF subtypes in vitro and in vivo (Aims 1 & 2). And lastly 4) since our knowledge of IL-6, metabolic alterations, CAF subtypes in pancreatic tumorigenesis has been gathered majorly from premalignant PanIN and invasive PDAC, to address this gap in knowledge, we will also compare and contrast IPMN organoids with PanIN and PDAC organoids to advance our understanding of the understudied IPMN (Aims 1 & 2). The success of our application will be transformative to clinical care of patients with IPMN and may be applicable to other known high-risk groups (i.e. patients with chronic pancreatitis, familial mutations, diabetes) for pancreatic cancer.

项目总结/文摘